玻璃体腔注射曲安奈德治疗葡萄膜炎致黄斑水肿临床研究  

Clinical study on triamcinolone acetonide as the treatment for macular edema caused by uveitis

作　　者：刘李平[1] 任兵[1] 练海东[2] 曹芃[1] 曹小鹏[1] 

机构地区：[1]解放军第474医院眼科医院全军眼科中心,乌鲁木齐830013 [2]石河子大学医学院第一附属医院眼科

出　　处：《临床眼科杂志》2011年第3期233-235,共3页Journal of Clinical Ophthalmology

摘　　要：目的观察玻璃体腔注射曲安奈德（TA）治疗葡萄膜炎致黄斑水肿的疗效及安全性。方法回顾性分析我院眼科门诊于2008年10月至2010年4月明确诊断为葡萄膜炎致黄斑水肿病例共56例（64只眼）,均给予玻璃体腔注射TA注射液,联合散瞳药物等治疗,随访1~2个月,观察视力、眼压、眼前后节情况进行疗效分析。结果 TA治疗后与治疗前比较,视力明显提高（P〈0.001）,相干光断层扫描（OCT）示黄斑中心视网膜厚度（CMT）明显变薄,由术前的平均（568±94）μm降至约（238±41）μm（P〈0.001）,黄斑水肿减轻,未见与药物有关的眼部和全身不良反应。结论葡萄膜炎并发黄斑水肿患者给予玻璃体腔注射TA可安全、有效提高视力、控制炎症及预防并发症。Objective To investigate the clinical efficacy of intravitreal injection of triamcinolone acetonide as the treatment for macular edema caused by uveitis.Methods The research is retrospective,noncomparative,and consecutive.It is confirmed that macular edema caused by uveitis with 64 eyes of 56 patients,then injects triamcinolone acetonide（TA,0.1 ml 40 mg/L） into vitreous body cavity.After operation the follow-up time was 1-2 months,whereafter,to detect visual acuity,intraocular pressure,inflammation reaction,fundus situation.Results The central macular thickness（CMT） in treatment group became obviously thinner（P0.001）,The visual acuity of the treatment group increased more than that of preinjection（P 0.001）.The untoward reaction of triamcinolone acetonide not been discovered.Conclusion Intravitreal injection of triamcinolone acetonide is a safe and effective method for neovascularization disease and could effectively improve eyesight,control inflammation and to prevent complications.

关 键 词：葡萄膜炎 黄斑水肿 曲安奈德 

分 类 号：R773.9[医药卫生—眼科]